Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Winter

Showing results (131-140 of 252) with videos related to

Pageof 26
Sort By:
Bone Marrow Transplantation|July 22, 1999
Immunohistochemical detection of breast cancer cells in paired peripheral blood progenitor cell specimens collected after cytokine or cytokine and myelosuppressive chemotherapyM B Kleinman, E L Wiley, M Guo, et al.
Leukemia & Lymphoma|August 22, 2012
Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidationRupali Roy, Andrew M Evens, David Patton, et al.
Blood|November 1, 1983
Estrogen receptor analysis in chronic lymphocytic leukemiaS T Rosen, Z Maciorowski, F Wittlin, et al.
British Journal of Haematology|August 10, 2013
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomasAndrew M Evens, Steven T Rosen, Irene Helenowski, et al.
Blood Advances|June 16, 2023
Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphomaJia Ruan, Jasmine Zain, Brett Palmer, et al.
Leukemia Research|September 17, 2022
Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 studyShuo Ma, Steven T Rosen, Maria Winqvist, et al.
Vaccine|April 27, 2000
Immune responses induced by recombinant BCG strains according to level of production of a foreign antigen: malEH Himmelrich, R Lo-Man, N Winter, et al.
Infection and Immunity|February 13, 2001
Induction of neutralizing antibodies against diphtheria toxin by priming with recombinant Mycobacterium bovis BCG expressing CRM(197), a mutant diphtheria toxinE N Miyaji, R P Mazzantini, W O Dias, et al.
Journal of the American College of Radiology : JACR|September 25, 2008
ACR Appropriateness Criteria on Hodgkin's lymphoma: favorable prognosis stage I and IIPrajnan Das, Andrea Ng, Louis S Constine, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 11, 2010
A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphomaOmer N Koç, Charles Redfern, Peter H Wiernik, et al.
Pageof 26

Showing results (131-140 of 252) with videos related to

Sort By:
Pageof 26
Bone Marrow Transplantation|July 22, 1999
Immunohistochemical detection of breast cancer cells in paired peripheral blood progenitor cell specimens collected after cytokine or cytokine and myelosuppressive chemotherapyM B Kleinman, E L Wiley, M Guo, et al.
Leukemia & Lymphoma|August 22, 2012
Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidationRupali Roy, Andrew M Evens, David Patton, et al.
Blood|November 1, 1983
Estrogen receptor analysis in chronic lymphocytic leukemiaS T Rosen, Z Maciorowski, F Wittlin, et al.
British Journal of Haematology|August 10, 2013
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomasAndrew M Evens, Steven T Rosen, Irene Helenowski, et al.
Blood Advances|June 16, 2023
Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphomaJia Ruan, Jasmine Zain, Brett Palmer, et al.
Leukemia Research|September 17, 2022
Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 studyShuo Ma, Steven T Rosen, Maria Winqvist, et al.
Vaccine|April 27, 2000
Immune responses induced by recombinant BCG strains according to level of production of a foreign antigen: malEH Himmelrich, R Lo-Man, N Winter, et al.
Infection and Immunity|February 13, 2001
Induction of neutralizing antibodies against diphtheria toxin by priming with recombinant Mycobacterium bovis BCG expressing CRM(197), a mutant diphtheria toxinE N Miyaji, R P Mazzantini, W O Dias, et al.
Journal of the American College of Radiology : JACR|September 25, 2008
ACR Appropriateness Criteria on Hodgkin's lymphoma: favorable prognosis stage I and IIPrajnan Das, Andrea Ng, Louis S Constine, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 11, 2010
A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphomaOmer N Koç, Charles Redfern, Peter H Wiernik, et al.
Pageof 26